WTWenxi Tan

Wenxi Tan

*This is an algorithmically generated author record based on publicly available information.

Wenxi Tan has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Haihua Feng

    Jilin University

    2 shared publications
  • Baihe Zhan

    Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun 130062, China

    1 shared publication
  • Baoyu Zhang

    Jilin Univ, Inst Zoonosis, State Key Lab Diag & Treatment Severe Zoonot Infec, Key Lab Zoonosis Res,Minist Educ, Changchun 130062, Peoples R China

    1 shared publication
  • Benzheng Zhao

    Department of Obstetrics and Gynecology, Second Hospital of Jilin University , Changchun 130041 , China

    1 shared publication
  • Bingfeng Leng

    Shenzhen Beichen Biotech Co Ltd, Shenzhen 518057, Peoples R China

    1 shared publication
  • Haiyan Qin

    Key Laboratory of Zoonosis, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, People’s Republic of China

    1 shared publication

Latest Publications

  • Natural medicine can substitute antibiotics in animal husbandry: protective effects and mechanisms of rosewood essential oil against Salmonella infection

    by Lanqiao Wang, Juan Fang, Heng Wang, Baoyu Zhang, Nan Wang, Xinyu Yao, He Li, Jiazhang Qiu, Xuming Deng, Bingfeng Leng, et al.


  • Dehydroandrographolide Improvement of Acetaminophen-Induced Acute Liver Failure

    by Lu Ding, Wenxi Tan, Yunfei Wei, Hao Yu, Lilei Zhao, Jiaqi Cheng, Haihua Feng


  • Open Access

    Metastasis from small cell lung cancer to ovary: A case report

    by Benzheng Zhao, Weixin Zhao, Yang Xia, Jian Liu, Yuan Wang, Tianjiao Song, Wenxi Tan, Shuhua Zhao

    Small cell lung cancer (SCLC) rarely metastasizes to the ovary, and is difficult to diagnose given its overlapping clinical features and histological characteristics with primary ovarian cancer. Since therapies for SCLC and primary ovarian cancer differ, it is important to determine the original site of ovarian lesions. This report describes the differential diagnosis of metastatic from primary ovarian cancer. A 46-year-old Chinese woman with a history of SCLC, confirmed by transbronchial lung biopsy in August 2018, presented with abdominal distension in December 2018. Ultrasound examination and whole abdomen computed tomography showed one mass in each ovary. A provisional diagnosis of ovarian tumor was given. A palliative total abdominal hysterectomy and bilateral salpingo-oophorectomy was performed; and three postoperative courses of chemotherapies. The patient died from multiple organ failure in May 2019. Metastatic ovarian cancer from SCLC was determined based on characteristic histological and immunohistochemical staining.

  • Gomphrena globosa L. extract alleviates carbon tetrachoride-induced liver injury in mice by activating antioxidant signaling pathways and promoting autophagy

    by Yunfei Wei, Wenxi Tan, Haiyan Qin, Meiyu Jin, Hao Yu, Jiaqi Cheng, Haihua Feng

    Background Carbon tetrachloride (CCl4) is highly toxic to animal liver and is a major contributor to liver injury. Gomphrena globosa L. (GgL) is an edible plant with anti-inflammation and antioxidation properties. The aim of this study was to investigate the potential therapeutic effects of GgL on liver injury. Methods and results A model of chronic liver injury in mice was established by intraperitoneal injection of CCl4 (0.4 mL/kg) for 3 weeks, and the mice were treated intraperitoneally with different concentrations of GgL crude extract (GgCE; 100, 200, 300 mg/kg) or Bifendatatum (Bif; 20 mg/kg) in the last 2 weeks. The results showed that GgCE treatment alleviated the liver injury, improved the pathological changes caused by CCl4 on the mice liver, and enhance the antioxidant capacity. We also found that GgCE increased the expression of antioxidant stress related proteins, decreased the phosphorylation levels of autophagy related proteins PI3K and mTOR, and decreased the expression of LC3 II and P62 proteins. Conclusion These results suggest that GgCE alleviated CCl4-induced chronic liver injury in mice by activating antioxidant signaling pathways and promoting autophagy, indicating a potential therapeutic effect of GgCE on liver injury.


  • Open Access

    Pogostone Enhances the Antibacterial Activity of Colistin against MCR-1-Positive Bacteria by Inhibiting the Biological Function of MCR-1

    by Shengnan Xie, Li Li, Baihe Zhan, Xue Shen, Xuming Deng, Wenxi Tan, Tianqi Fang

    The emergence of the plasmid-mediated colistin resistance gene mcr-1 has resulted in the loss of available treatments for certain severe infections. Here we identified a potential inhibitor of MCR-1 for the treatment of infections caused by MCR-1-positive drug-resistant bacteria, especially MCR-1-positive carbapenem-resistant Enterobacteriaceae (CRE). A checkerboard minimum inhibitory concentration (MIC) test, a killing curve test, a growth curve test, bacterial live/dead assays, scanning electron microscope (SEM) analysis, cytotoxicity tests, molecular dynamics simulation analysis, and animal studies were used to confirm the in vivo/in vitro synergistic effects of pogostone and colistin. The results showed that pogostone could restore the bactericidal activity of colistin against all tested MCR-1-positive bacterial strains or MCR-1 mutant–positive bacterial strains (FIC < 0.5). Pogostone does not inhibit the expression of MCR-1. Rather, it inhibits the binding of MCR-1 to substrates by binding to amino acids in the active region of MCR-1, thus inhibiting the biological activity of MCR-1 and its mutants (such as MCR-3). An in vivo mouse systemic infection model, pogostone in combination with colistin resulted in 80.0% (the survival rates after monotherapy with colistin or pogostone alone were 33.3% and 40.0%) survival at 72 h after infection of MCR-1-positve Escherichia coli (E. coli) ZJ487 (blaNDM-1-carrying), and pogostone in combination with colistin led to one or more order of magnitude decreases in the bacterial burdens in the liver, spleen and kidney compared with pogostone or colistin alone. Our results confirm that pogostone is a potential inhibitor of MCR-1 for use in combination with polymyxin for the treatment of severe infections caused by MCR-1-positive Enterobacteriaceae.